Using kallikrein-related peptidases (KLK) as novel cancer biomarkers

Thrombosis and Haemostasis

Volumn 101, Issue 2, 2009, Pages 222-224

  Schmitt, Manfred ^a   Magdolen, Viktor ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; KALLIKREIN; MESSENGER RNA; TUMOR MARKER; ISOENZYME;

BONE CANCER; BRAIN CANCER; BREAST CANCER; CANCER STAGING; COLON CANCER; DNA METHYLATION; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HEAD AND NECK CANCER; KIDNEY; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN CANCER; SOFT TISSUE CANCER; STOMACH CANCER; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; NEOPLASM; PATHOLOGY; PROGNOSIS;

GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOENZYMES; KALLIKREINS; NEOPLASMS; PROGNOSIS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 62449102685     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-01-0026     Document Type: Editorial

References (34)

1. Frey EK. Zusammenhänge zwischen Herzarbeit und Nierentätigkeit. Arch Klin Chir 1926; 142: 663-669,
2. Frey EK, Kraut H. Über einen von der Niere aus-geschiedenen, die Herztätigkeit anregenden Stoff, Hoppe-Seyler's Z Physiol Chem 1926; 157: 32-61.
3. Kraut II, et al. Über die Inaktivierung des Kallikre-ins. Hoppe-Seyler's Z Physiol Chem 1930; 192: 1-21.
4. Werle E, et al. Über dieWirkung des Kallikreins auf den isolierten Darm und über eine neue darmkontra-hierende Substanz. Biochem Z 1937; 289: 217-233.
5. Sainz IM, et al. Fifty years of research on the plasma kallikrein-kinin system: from protein structure and function to cell biology and in-vivo pathophysiology. Thromb Haemost 2007; 98: 77-83.
6. Borgoño CA, Diamandis EP The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004; 4: 876-890.
7. Lundwall A, Brattsand M. Kallikrein-related peptidases. Cell Mol Life Sci 2008; 65: 2019-2038.
8. Schedlich LJ, et al. Primary structure of a human glandular kallikrein gene. DNA 1987; 6: 429-437.
9. Rao AR, et al. The discovery of prostate-specific antigen. Br J Urol Int 2008; 101: 5-10.
10. Lundwall A, Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 1987; 214: 317-322.
11. Gan L, et al. Sequencing and expression analysis of the serine protease gene cluster located in chromosome 19q13 region. Gene 2000; 257: 119-130.
12. Harvey TJ, et al. Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4. J Biol Chem 2000; 275: 37397-37406.
13. Yousef GM, et al. Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem Biophys Res Commun 2000; 276: 125-133.
14. Lundwall A, et al. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol Chem 2006; 387: 637-641.
15. Clements JA, et al. The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci 2004;41:265-312.
16. Klokk TI, et al. Human Tissue Kallikreins - A Family with many surprises. Turk J Biochem 2006; 31: 69-78.
17. Shaw JL, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 2007; 53: 1423-1432.
18. Paliouras M, et al. Human tissue kallikreins: the cancer biomarker family. Cancer Lett 2007; 249: 61-79.
19. Harbeck N, et al. Tumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms. Crit Rev Clin Lab Sci 2007; 44: 179-201.
20. Folgueras AR, et al. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol, 2004; 48: 411-424.
21. Ramirez ML, et al. Beyond prostate-specific antigen: alternate serum markers. Prostate Cancer Prostatic Dis 2008; 11: 216-229.
22. Emami N, Diamandis EP. Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers, Clin Chem 2008; 54: 1600-1607.
23. Dorn J, et al. Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients. Clin Cancer Res 2007; 13: 1742-1748.
24. Talieri M, et al. Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma. Thromb Haemost 2004; 91: 180-186.
25. Yousef GM, et al. Differential expression of Kallikrein gene 5 in cancerous and normal testicular tissues. Urology 2002; 60: 714-718.
26. Prezas P, et al. The role of human tissue kallikreins 7 and 8 in intracranial malignancies. Biol Chem 2006; 387: 1607-1612.
27. Stavropoulou P, et al. Expression analysis and prognostic significance of human kallikrein 11 in prostate cancer. Clin Chim Acta 2005; 357: 190-195.
28. Thomadaki H, et al. Treatment of PC3 prostate cancer cells with mitoxanthrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11. Thromb Haemost 2009; 101:373-380.
29. Papachristopoulou G, et al. Expression analysis and study of KLK4 in benign and malignant breast tumors. Thromb Haemost 2009; 101: 381-387.
30. Kontourakis P, et al. Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis. Thromb Haemost 2009; 101: epub ahead of print Jan 15, 2009.
31. Talieri M, et al. Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer. Thromb Haemost 2009; in print.
32. Borgoño CA, et al. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer, Clin Cancer Res 2006; 12: 1487-1493.
33. Bhoola KD, et al. Current status of tissue kallikrein inhibitors: importance in cancer. Curr Opin Investig Drugs 2007; 8:462-468.
34. Debela M, et al. Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7. Biol Chem 2008; 389: 623-632.